ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

No Tumor Recurrence After Renal Cell Carcinoma Resected Kidney Transplantation – 5 Year Follow Up

M. Zwierzchoniewska,1 K. Fong,1 D. Patel,1 L. Mou, W. Lim,2 B. He,1 L. Delriviere.1

1Western Australian Kidney Transplant Surgery Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
2Western Australian Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

Meeting: 2015 American Transplant Congress

Abstract number: D42

Keywords: Donors, Kidney transplantation, marginal, Outcome, Tumor recurrence

Session Information

Session Name: Poster Session D: Diabetes/Metabolic/Bone/Malignancy/Pregnancy

Session Type: Poster Session

Date: Tuesday, May 5, 2015

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

INTRODUCTION:

Organ shortage remains the single most significant impediment to increasing low rate of kidney transplantation. One of the strategies to improve it, is a utilisation of kidneys from patient undergoing radical nephrectomy for small renal cell cancer (sRCC). The sRCC is known to have low risk for cancer transmission. In 2007, our centre have established a program to utilise kidney transplants restored from this source, known as Tumor Resected Kidneys (TRK).

METHODS:

Between 2007 and 2012, 27 patients with End Stage Renal Disease aged < 55 and > 65 received TRK transplant. After nephrectomy, the tumor was removed and kidney was transplanted into unrelated recipient selected based on matched blood group and negative cross match test. TRK transplant inclusion criteria were: tumor size < 3cm with histopathologically confirmed clear margins. Patients were followed up with kidney US and chest X-ray every 3 months during first 2 years, and then annually, indefinitely.

RESULTS:

The total of 27 TRK were transplanted. Recipients: 14 males,13 females; aged 64.4 years (SD7.2). Donors: 12 males, 14 females aged 57.1 years (SD12.3). Creatinine of the recipient at the time transplant was: 726.4 ¯o;mol/l (SD 240.4). Further at 6; 12; 24 and 60 months post transplant was respectively: 166.5(SD65.4)(n=27);176.4(SD78.7)(n=27);215.6(SD168.8)(n=25)and185.5(SD116.4)(n=4); (all ¯o;mol/l) . All recipients received triple immunosuppression. Removed sRCC size was 2.65 cm (SD1.16). Complications : 4 cases of urinary leak treated successfully; one graft removed due to infection; 1 pseudoaneurysm treated with embolization. There were 7 deaths among recipients in the late post transplant period: 1 due to colon cancer, 1 due to CMV reactivation, the rest due to cardiovascular disease and worsening graft function. Recipient survival rate was: 96.3 % and 92.6% at 1 and 2 years respectively, and 82.5% at 5 years. There was no recurrence of the tumor to date.

CONCLUSIONS:

Selected candidates can benefit from tumor resected kidney transplants, achieving good renal function without tumor recurrence. Complications rate is low. Survival rates are comparable with population of recipients receiving cadaveric kidney grafts. It can be important source of kidney grafts to increase the donor pool.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Zwierzchoniewska M, Fong K, Patel D, Mou L, Lim W, He B, Delriviere L. No Tumor Recurrence After Renal Cell Carcinoma Resected Kidney Transplantation – 5 Year Follow Up [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/no-tumor-recurrence-after-renal-cell-carcinoma-resected-kidney-transplantation-5-year-follow-up/. Accessed May 16, 2025.

« Back to 2015 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences